Middleton E T, Rajaraman C J, O'Brien D P, Doherty S M, Taylor A D
Centre for Metabolic Bone Disease, Hull Royal Infirmary, Hull, UK.
Br J Neurosurg. 2008 Apr;22(2):252-6. doi: 10.1080/02688690701824354.
Vertebroplasty provides an effective means of treating painful vertebral lesions although the majority of the literature relates to vertebroplasty using PMMA cement. The purpose of this study is to assess the safety and efficacy of vertebroplasty using Cortoss, a recently developed bis-GMA resin. Our newly established vertebroplasty service exclusively uses Cortoss cement and has a patient database which is updated on a regular basis using the medical records. To date, there are 34 patients on this database, mean age 66, in whom a vertebroplasty has been performed on 42 vertebral lesions with a mean of 2.2 ml of Cortoss injected into each lesion. The mean duration of follow up was 9.5 months. Eighty-two per cent of patients reported an improvement in their symptoms, while 79% required less analgesia post vertebroplasty. A total of 88.2% experienced no significant complications. In 38% there was an asymptomatic leakage of Cortoss. Four patients (11.8%) experienced significant complications: one asymptomatic PE, one episode of transient radicular leg pain, one generalized rash and one patient suffered retropulsion of the Cortoss due to further vertebral malignancy. Cortoss vertebroplasty provides comparable efficacy and safety to the published literature for PMMA.
椎体成形术为治疗疼痛性椎体病变提供了一种有效的方法，尽管大多数文献涉及使用聚甲基丙烯酸甲酯（PMMA）骨水泥的椎体成形术。本研究的目的是评估使用最近开发的双酚A缩水甘油醚（bis-GMA）树脂Cortoss进行椎体成形术的安全性和有效性。我们新建立的椎体成形术服务仅使用Cortoss骨水泥，并有一个患者数据库，该数据库使用病历定期更新。迄今为止，该数据库中有34名患者，平均年龄66岁，对42个椎体病变进行了椎体成形术，每个病变平均注入2.2毫升Cortoss。平均随访时间为9.5个月。82%的患者报告症状有所改善，而79%的患者椎体成形术后所需镇痛药物减少。共有88.2%的患者未出现明显并发症。38%的患者出现Cortoss无症状渗漏。4名患者（11.8%）出现严重并发症：1例无症状肺栓塞，1例短暂性神经根腿痛发作，1例全身性皮疹，1例患者因椎体进一步恶变导致Cortoss后凸。与已发表的关于PMMA的文献相比，Cortoss椎体成形术具有相当的疗效和安全性。
